Selecta Biosciences was a big mover last session, as its shares rose over 6% on the day. The move came after the company announced data from its ongoing Phase 2 trial of SEL-212 (SVP-Rapamycin in combination with the uricase enzyme pegsiticase), which is being developed for patients with chronic severe gout. This led to far more shares changing hands than in a normal session. This continues the recent uptrend for the company as the stock is now up roughly 27% in the past one-month time frame.

None of the estimates for this stock were revised over the past 30 days. The Zacks Consensus Estimate also remained unchanged over the same time frame. Yesterday’s price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

Selecta Biosciences currently carries a Zacks Rank #4 (Sell) while its Earnings ESP is 0.00%.

Selecta Biosciences, Inc. Price

 

Selecta Biosciences, Inc. Price | Selecta Biosciences, Inc. Quote

A better-ranked stock in the Medical - Biomedical and Genetics space is VIVUS, Inc. , sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

3 Top Picks to Ride the Hottest Tech Trend                   

Zacks just released a Special Report to guide you through a space that has already begun to transform our entire economy...

Last year, it was generating $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for those who make the right trades early. Download Report with 3 Top Tech Stocks >>